Jose Manuel Otero Sells 3,016 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) COO Jose Manuel Otero sold 3,016 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $6.40, for a total value of $19,302.40. Following the transaction, the chief operating officer directly owned 125,460 shares of the company’s stock, valued at approximately $802,944. The trade was a 2.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO traded up $0.02 during midday trading on Friday, reaching $6.29. 659,585 shares of the company’s stock traded hands, compared to its average volume of 1,093,850. The company has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $7.62. Lexeo Therapeutics, Inc. has a 1 year low of $1.45 and a 1 year high of $10.99. The company has a market cap of $459.11 million, a P/E ratio of -2.33 and a beta of 1.78.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. acquired a new position in Lexeo Therapeutics during the fourth quarter worth $4,598,000. Vestal Point Capital LP raised its holdings in shares of Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after acquiring an additional 1,225,000 shares during the period. Virtus Investment Advisers LLC acquired a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $270,000. Wellington Management Group LLP acquired a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $826,000. Finally, Susquehanna Portfolio Strategies LLC grew its holdings in shares of Lexeo Therapeutics by 14.4% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 26,205 shares of the company’s stock valued at $260,000 after purchasing an additional 3,296 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Lexeo Therapeutics in a research report on Monday, December 1st. They set an “overweight” rating and a $19.00 price target for the company. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Raymond James Financial started coverage on Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price target on the stock. Finally, Chardan Capital reiterated a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.